Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL ARTICLE

Does atopy affect the course of viral pneumonia?

S.B. Erdem a,*, D. Can a, S. Girit b, F. Çatal c, V. Şen d, S. Pekcan e, H. Yüksel f, A. Bingöl g, I. Bostancı h, D. Ergel i, R. Ersu j

a Dr Behcet Uz Children’s Hospital, Department of Pediatric Allergy, Izmir, Turkey
b Kartal Dr Lütfü Kirdar Training and Research Hospital, Pediatric Pulmonology, Istanbul, Turkey
c İnönü University Faculty of Medicine, Department of Allergy Immunology, Malatya, Turkey
d Dicle University Faculty of Medicine, Department of Pediatrics, Diyarbakir, Turkey
e Necmettin Erbakan University, Meram Medical Faculty, Department of Allergy Immunology, Konya, Turkey
f Celal Bayar University Medical Faculty, Department of Allergy Immunology, Manisa, Turkey
g Akdeniz University Faculty of Medicine, Department of Allergy Immunology, Antalya, Turkey
h Dr. Sami Ulus Obstetrics and Child Health and Diseases Training and Research Hospital, Department of Allergy Immunology, Ankara, Turkey
i Adnan Menderes University Medical Faculty, Department of Allergy Immunology, Aydın, Turkey
j Marmara University Faculty of Medicine, Department of Pediatric Pulmonology, Istanbul, Turkey

Received 14 February 2017; accepted 6 April 2017
Available online 17 June 2017

KEYWORDS
Atopy;
Children;
Viral pneumonia

Abstract

Background: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised with viral pneumonia.

Methods: Children between the ages of 1 and 6 years hospitalised due to viral pneumonia between the years of 2013 and 2016 were included in this multicentre study. Patients were classified into two groups as mild-moderate and severe according to the course of pneumonia. Presence of atopy was evaluated with skin prick tests. Groups were compared to evaluate the risk factors associated with severe viral pneumonia.

Results: A total of 280 patients from nine centres were included in the study. Of these patients, 163 (58.2%) were male. Respiratory syncytial virus (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%) were isolated from respiratory samples. Eighty-five (30.4%) children had severe pneumonia. Atopic sensitisation was found in 21.4% of the patients. Ever wheezing (RR: 1.6, 95% CI: 1.1–2.4), parental asthma (RR: 1.5, 95% CI: 1.1–2.2), other allergic diseases in the family (RR: 1.8, 95% CI: 1.2–2.9) and environmental tobacco smoke (RR: 1.6, 95% CI: 1.1–3.5) were more common in the severe pneumonia group.

Abbreviations: RV, rhinovirus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; RT-PCR, real-time reverse transcription polymerase chain reaction; SPT, skin prick tests; BMI, body mass index; ETS, environmental tobacco smoke exposure.

* Corresponding author.
E-mail address: semihabahceci@hotmail.com (S.B. Erdem).

https://doi.org/10.1016/j.aller.2017.04.003
0301-0546/© 2017 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.
Introduction

Interaction between asthma and viral infections has been known for a very long time. Attention has been drawn in many studies to decreased antiviral response in patients with asthma. Epithelium damage, disrupted epithelium repair mechanisms, inflammation and insufficient immune response that occur in asthma cause these patients to become more sensitive to airway irritants as well as viral infections. Atopy, which refers to the genetic tendency to develop allergic diseases such as allergic rhinitis, asthma and atopic dermatitis and viral infections, disrupts the integrity of the epithelial barrier by way of synergic effect on the respiratory tract. This damage on the respiratory epithelium causes the onset of inflammation, thus triggering wheezing episodes and asthma. Inflammation in the respiratory tract due to atopy in addition to the disruption of the epithelial barrier integrity places these patients under risks of severe viral lower respiratory tract infections.

Atopic children are at more risk for severe pneumonia during pandemic influenza epidemics. Also, the first Rhinovirus (RV) infection in patients with asthma is generally in the form of lower respiratory tract infection and it is more severe and lasts longer. It was put forth in a prospective cohort study that the risk of hospitalisation due to severe Respiratory syncytial virus (RSV) infection is greater in atopic children in comparison with the control group. It is also reported that asthma and atopic dermatitis increase the risk of pneumococcal infections. Recent studies show that atopic sensitisation emerges prior to respiratory tract infections. Both viral illness and allergic sensitisation/exposure increase risks of severe respiratory tract diseases that require hospitalisation. The objective of this study was to examine the effects of the presence of atopy on the course of disease in children hospitalised with viral pneumonia. We hypothesised that atopic children are at increased risk for severe pneumonia with viral infections.

Materials and method

All children between the ages of 1 and 6 years hospitalised with a viral pneumonia between 01/11/2013 and 01/01/2016 were included in this multicentre prospective study. Cases with chronic disease including asthma, gastro-esophageal reflux, tracheomalacia, tuberculosis, congenital heart disease, cystic fibrosis, primary ciliary dyskinesia, vascular ring, bronchopulmonary dysplasia, or immune deficiency were excluded from the study. Presenting symptoms of the patients, laboratory findings, radiological findings and duration of hospitalisation were recorded.

Conclusions: When patients with mild–moderate pneumonia were compared to patients with severe pneumonia, frequency of atopy was not different between the two groups. However, parental asthma, ever wheezing and environmental tobacco smoke exposure are risk factors for severe viral pneumonia in children.

© 2017 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Atopy

Atopy is defined as positive skin prick tests (SPT) to one or more allergens.

Virus detection and identification

Virus detection and identification were carried out in the nasopharyngeal aspirates example via real-time reverse transcription polymerase chain reaction (RT-PCR) method (Fast Track Diagnostics Luxembourg S.’a.r.l).

Skin prick test

Presence of atopy was evaluated by skin prick tests (SPT). All participants had SPTs for Dermatophagoides pteronyssinus, Dermatophagoides farinae, Alternaria alternata, cat, grass mix (Phleum pratense, Poa pratensis, Dactylis glomerata, Lolium perenne, Festuca pratensis, and Avena eliator), tree mix (Betula verrucosa, Alnus glutinosa, and Corylus avellana), Olea europea, Blatella germanica, histamine, and negative controls. Standardised core allergen extracts and controls were provided by ALK-Abello, Horsholm, Denmark. The tests were administered using prick test device on the volar surface of both forearms and recorded after 15 min and considered as positive if the mean wheal diameter was 3 mm larger compared to the negative control. Positive SPT was defined as a wheal >3 mm to one or more allergens. SPT of patients who had received corticosteroid therapy were performed four weeks after hospital discharge. On the other hand, SPT were performed after completion of pneumonia treatment in patients who had not received steroids.

Severity of viral pneumonia

Patients were classified into two groups as mild–moderate and severe according to the course of pneumonia. The patients were considered to have severe pneumonia if at least one of the following criteria was present1:

- SpO2 <90% (in ambient air)
- 2nd or 3rd stage intensive care or mechanical ventilation support requirement
- Development of atelectasis or effusion
- Impaired consciousness (tendency to sleep, lethargy, confusion, unresponsiveness to painful stimulant)
- Excessive dehydration
- Apnoea
Risk factors

All risk factors that may cause a severe viral pneumonia course were examined. These risk factors included gender, body mass index (BMI), education status of the family, whether or not influenza vaccination had been given, environmental tobacco smoke exposure (ETS), presence of atopic disease in the patient, presence of atopic disease in the family, causative agent, type of allergen, and the presence of pets.

Statistical analysis

Data analysis was carried out via SPSS 22.0 (IBM statistics for Windows version 22, IBM Corporation, Armonk, New York, United States) and Medcalc 14 (Acacialaan 22, B-8400 Ostend, Belgium) software. Shapiro–Wilk test was used to examine whether the data fit normal distribution or not and the variance homogeneity of the data was examined via Levene test. Independent-Samples T test together with Bootstrap results was used to compare two independent groups, Mann–Whitney U test was used with Monte Carlo simulation technique. Pearson Chi-Square and Fisher Exact tests were tested via Monte Carlo Simulation technique for the comparison of categorical data. Relative risk values were calculated in order to examine the ratio between developing a disease in those with a risk factor and those that do not. Logistic regression test was used to calculate the odds-ratio for quantitative explanatory variables with statistically significant binary (diotome) response variables. Quantitative data were expressed in the tables as mean ± sd (standard deviation), median ± IQR (Interquartile Range) and as median Range (Maximum–Minimum) values. Categorical data were expressed as n (number) and percentages (%). Data were examined at a confidence level of 95% and a p value of less than 0.05 was accepted as statistically significant.

Ethical approval

Approval was taken from Izmir Dr. Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital Non-Pharmacologic Clinical Studies Ethical Council (no. 2013/54).

Results

A total of 280 patients from different geographical regions of Turkey were included in the study. A total of 31 patients whose medical records were missing could not be included in the study. There were 163 (58.2%) males with an average age of 32.9 ± 21.08 (min 11–max 72) months and BMI of 16.4 (min 10.8–max 29.5). The average duration of hospitalisation was 9.2 ± 7.90 (min 1–max 60) days. Viral agents included RSV (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (hMPV) (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%).

When the history of atopy in the family was questioned, 16% had parental asthma, 6.9% had family history of allergic rhinitis, 3.6% eczema and 6.0% food/drug allergy in the family. Forty-eight percent of the patients had ever wheezing, 5.2% had allergic rhinitis, 2% had eczema and 5.2% had food/drug allergy. Environmental tobacco smoke exposure was present in 44.1% of the patients. When the family education status was evaluated 33.7% mothers had high-school education and 46.9% of the fathers had high-school education. Three percent of the patients had received influenza vaccine and 6.4% had pets in their homes (Table 1).

Atopy was found in 60 (21.4%) patients; most frequent sensitisations were mite (11.4%), grass/pollen mixture (7.1%) and Alternaria (5%). Atopy was more frequent in patients with influenza (29.2%) and rhinovirus (25%) infections (p = 0.196) but no statistically significant difference was found. Atopic patients were older compared to non-atopic patients with viral pneumonia (p = 0.001).

One hundred and ninety-five patients (69.6%) had mild–moderate, 85 (30.4%) had severe pneumonia. When compared to patients with mild or moderate pneumonia, patients with severe pneumonia were found to carry a significantly greater relative risk (RR) in terms of ever wheezing (RR: 1.6, 95% CI: 1.1–2.4), parental asthma (RR: 1.5, 95% CI:1.09–2.23), other allergic diseases in the family (RR: 1.8, 95% CI: 1.16–2.9) and ETS (RR: 1.6, 95% CI: 1.1–3.5) respectively. The education status of the parents, existence of pets, whether the patient or the family members had had influenza vaccination during this year or in the past were not associated with the severity of pneumonia (Tables 2a and 2b).

Not surprisingly, patients with severe pneumonia had longer duration of hospitalisation (p = 0.001) and their body mass indexes were lower (p = 0.032). Children with severe pneumonia had lower number of lymphocytes (p < 0.001) and eosinophils (p = 0.003), and higher number of neutrophils (p < 0.001) compared to mild to moderate group.

Atopy was detected in 17.6% of children with severe pneumonia and 16.4% in mild–moderate pneumonia (p = 0.736). Even though no statistically significant difference was found in terms of atopy in the group with severe pneumonia, ever wheezing (p = 0.008) and parental asthma (p = 0.004) were observed more frequently in children with severe pneumonia (Table 2b).

Discussion

In this study, there was no effect of atopic sensitisation on the severity of viral pneumonia in children. However, history of allergic diseases such as ever wheezing, atopic dermatitis and food/drug allergy were associated with severe pneumonia.

Natural and acquired immunity of the airway is insufficient in asthma.12-14 Airway epithelium is a chemical, physical, and immunological barrier.15 In addition to holding the cells together, the airway epithelium tight junction regions act as a protective barrier that prevents harmful molecules and infectious agents from entering the tissue, by preventing their passage from the intracellular gaps between the molecules and ions.16-19 It has been shown that patients with asthma are more sensitive to allergens and environmental irritants due to defects in the epithelium barrier.20 Children generally face house allergens more during the first years of their lives. The risk
of developing asthma increases as a result of this sensitivity to allergens. It has been shown in studies that the exposure of lung epithelium to allergens with proteolytic activity such as house-dust mite, pollen, mould and fungi causes an increase in epithelial permeability by separating the tight junction regions between the epithelial cells. All respiratory tract viruses enter from the airway epithelium, replicate in the airway epithelium thus damaging both ciliated and non-ciliated respiratory tract epithelium cells. As a result, they cause necrosis, ciliostasis, loss of cilia and decrease in mucociliary clearance in the airway epithelium. Both atopy and viral infections cause loss of integrity in the epithelium barrier, which has a vital importance due to its synergic effect on the respiratory tract.

Forty-two percent of children who were hospitalised in intensive care units during the 2009–2010 pandemic influenza epidemic had asthma/atopic sensitisation, and H1N1-related severe respiratory tract infections were more common in atopic children in comparison with non-atopic children. In another study carried out during the same year, of the 33 children who had an asthma attack during the pandemic influenza epidemic, 66.7% had had an asthma attack.

### Table 1 Demographic and clinical findings of patients.

|                                      | n     | %     |
|--------------------------------------|-------|-------|
| **Atopy**                            | 60    | 21.4% |
| **Severity of pneumonia**            |       |       |
| Severe                               | 60    | 21.4% |
| Moderate                             | 122   | 44.1% |
| Well                                 | 101   | 34.5% |
| **Gender**                           |       |       |
| Male                                 | 163   | 58.2% |
| Female                               | 72    | 25.8% |
| **Education status of mother**       |       |       |
| Illiterate                           | 8     | 4.6%  |
| Moderate education                   | 108   | 36.1% |
| Well educated                        | 59    | 19.4% |
| **Education status of father**       |       |       |
| Illiterate                           | 3     | 1.7%  |
| Moderate education                   | 90    | 30.1% |
| Well educated                        | 82    | 27.8% |
| **History of atopy in the family**   | 64    | 25.8% |
| **History of atopy in the sibling**  | 25    | 10.1% |
| **Presence of another atopic disease**| 29  | 11.6% |
| **History of ever wheezing in the child** | 122 | 47.9% |
| **History of influenza vaccination in the family** | 17 | 7.3% |
| **History of influenza vaccination in the child** | 7   | 3%    |
| **Passive smoking**                  | 101   | 44.1% |
| **Pets**                             | 15    | 6.4%  |
| **PCR**                              |       |       |
| Adenovirus                           | 25    | 10.0% |
| Rhinovirus                           | 47    | 18.9% |
| HMPv                                 | 20    | 8.0%  |
| RSV                                  | 74    | 29.7% |
| Parainfluenza                        | 13    | 5.2%  |
| Influenza A                          | 51    | 20.5% |
| Coronavirus                           | 15    | 6.0%  |
| Bocavirus                            | 4     | 1.6%  |
| **Mean ± SD**                        |       |       |
| Age                                  | 32.9 ± 21.08 | 24 (72–11) |
| BMI                                  | 16.8 ± 2.51 | 16.4 (29.5–10.8) |
| Duration of Hospitalisation (day)    | 9.2 ± 7.90 | 7 (60–1) |
| Fever                                | 37.4 ± 0.96 | 37 (39.9–36) |
| HR                                   | 119.8 ± 23.56 | 114.5 (186–60) |
| RR                                   | 34.9 ± 10.83 | 32 (70–12) |
| SaO₂                                 | 95.1 ± 4.32 | 96 (100–72) |
| Haemoglobin                          | 11.4 ± 1.37 | 11.3 (16–7.6) |
| Leucocyte                            | 12,050.6 ± 4997.40 | 11,200 (31,280–11.9) |
| Lymphocyte                           | 37.5 ± 19.97 | 34.5 (85–2) |
| Monocyte                             | 7.3 ± 7.18 | 6.695 (79–0) |
| Neutrophil                           | 52.7 ± 22.47 | 54.3 (94.3–0) |
| Eosinophil                           | 1.7 ± 2.32 | 0.7 (13.8–0) |
| Basophile                            | 0.4 ± 0.40 | 0.3 (2.26–0) |
| Thrombocyte                          | 373,482.3 ± 123,195.68 | 366,000 (1,006,000–385) |

SD: standard deviation, max: maximum, min: minimum. PCR: polymerase chain reaction, BMI: body mass index, HR: heart beats per minute, RR: respiratory rate per minute, SaO₂: oxygen saturation.
Table 2a Distribution of risk factors according to the course of the disease.

| Pneumonia                  | Mild-moderate | Severe | p value | Relative risk (95% confidence interval) | p value for relative risk |
|----------------------------|---------------|--------|---------|----------------------------------------|--------------------------|
| Age                        | 31.3 ± 21.04  | 34.2 ± 20.84 | 0.823  | 1.3 (1.1-1.4)                           | <0.001                   |
| BMI                        | 17.2 ± 2.50   | 16.2 ± 2.42 | 0.032  |                                        |                          |
| Hospitalisation period     | 6.0 ± 3.0     | 9.0 ± 8.5   | <0.001 | 0.8 (0.7-0.8)                           | <0.001                   |
| Fever                      | 37.6 ± 1.6    | 36.8 ± 1.2  | 0.025  | 0.7 (0.5-0.9)                           | 0.024                    |
| SaO₂                       | 97.0 ± 3.0    | 95.0 ± 8.0  | <0.001 |                                        |                          |

Independent T test (Bootstrap) – Mann Whitney U test (Monte Carlo).
SD: standard deviation; IQR: interquartile range; BMI: body mass index; HR: heart beats per minute; RR: respiratory rate per minute; SaO₂: oxygen saturation.

Table 2b Distribution of risk factors according to the course of the disease.

| Gender                   | Mild-moderate | Severe | p value |
|--------------------------|---------------|--------|---------|
| Female                   | 74 (45.4)     | 32 (37.6) | 0.28   |
| Male                     | 89 (54.6)     | 53 (62.4) |       |
| Passive smoking          |               |        |        |
| N/A                      | 94 (61.0)     | 32 (43.8) | 0.016  |
| Yes                      | 60 (39.0)     | 41 (56.2) | 1.6 (1.1-3.5) | 0.016 |
| Pets                     |               |        |        |
| N/A                      | 147 (95.5)    | 71 (89.9) | 0.156  |
| History of asthma in the family |         |        |        |
| N/A                      | 145 (89.0)    | 63 (74.1) | 0.004  |
| History of eczema in the family |         |        |        |
| N/A                      | 156 (96.3)    | 82 (96.5) | 1      |
| History of allergic rhinitis in the family |     |        |        |
| N/A                      | 148 (91.9)    | 81 (95.3) | 0.431  |
| Sibling                  |               |        |        |
| N/A                      | 161 (99.4)    | 81 (95.3) | 0.049  |
| Application to another health centre prior to hospitalisation | | | |
| N/A                      | 91 (59.1)     | 33 (42.3) | 0.018  |
| Viral LRTI in the family |               |        |        |
| N/A                      | 141 (91.6)    | 64 (79.0) | 0.012  |
| Ever wheezing in the child |            |        |        |
| N/A                      | 90 (58.4)     | 31 (39.7) | 0.008  |
| Allergic rhinitis in the child |          |        |        |
| N/A                      | 151 (93.2)    | 83 (97.6) | 0.229  |
| Education status of mother |            |        |        |
| Illiterate               | 11 (6.8)      | 2 (2.4)  |        |
| Moderate education       | 6 (3.5)       | 4 (6.7)  |        |
| Well educated            | 75 (66.4)     | 32 (52.5) | 0.109  |
| Education status of father |            |        |        |
| Illiterate               | 2 (1.8)       | 1 (1.6)  | 0.208  |
| Moderate education       | 63 (55.8)     | 26 (42.6) |        |
| Well educated            | 48 (42.5)     | 34 (55.7) |        |

Pearson Chi Square Test (Monte Carlo) – Fisher Exact (Exact).
PCR: polymerase chain reaction, HMPv: human metapneumovirus, RSV: respiratory syncytial virus. LRTI: lower respiratory tract infection.
* Relative risk (95% confidence interval).
attack before but had not received a protective treatment for asthma, whereas 31.8% had their first asthma attack. Severe asthma attack, pneumonia and atelectasis develop more easily in atopic patients.5 However, no such difference has been determined in seasonal influenza.6,8 In our study the presence of atopy by a skin prick test was not a risk factor for severe viral pneumonia. However, we showed that ever wheezing and parental asthma, which are related with atopic structure, were associated with severe of pneumonia.

When volunteers are subject to in vivo RV inoculation, those with asthma have more severe symptoms in comparison with the controls.19 Experimental RV studies show that allergic sensitisation and exposure to allergens are related with increase in the severity of RV related lower respiratory tract infections and asthma exacerbations.1 Ducharme, FM et al.21 showed that almost in two-thirds of patients, predominantly pre-schoolers (those aged six years or older), viruses have been detected in their nasopharyngeal secretions, mainly RV and RSV. In our study, influenza (29.2%) and RV (25%) pneumonias were more frequent in atopic children, which supports the previous findings.

Effects of pollutants such as cigarettes are generally neglected in the existence of allergens and viruses.22 When a comparison was made between children hospitalised for community acquired pneumonia, duration of hospitalisation of children with two or more smoking family members in the house was longer, and that their intensive-care needs were greater.23 Previous studies reported that ETS for Gambian and Alaskan children and smoking of the mother for Finnish children are related with invasive pneumococcal disease.24–26 Jroundi et al.27 showed that smoking in the house was associated with a worse prognosis in children with pneumonia. As expected, ETS was a significant risk factor for severe pneumonia from our study. Jung et al.15 reported that other allergic diseases such as asthma and atopic dermatitis also increase the risk of pneumococcal infections. We also showed that the risk of severe pneumonia increased by 2.4 times (p < 0.001) for those who had a history of eczema.

Even simple nutritional changes may have effects on prevention of virus-induced disease.1 Lower body mass index (BMI) for our cases with severe pneumonia indicate the importance of nutritional support in virus-related pneumonia. Lazzerini et al.14 showed that pneumonia related fatality rates increase in cases with malnutrition. A study by Jroundi et al.28 supported these findings showing that prognosis is worse in children with weight-for-age Z score <1SD. Ahanchan et al.29 pointed out that nutritional support will decrease the recurrence of lower respiratory tract infections in children. Jroundi et al.30 studied 689 children with pneumonia and showed that cyanosis, paleness, prematurity and passive smoking were risk factors for worse prognosis, while ever wheezing or asthma story were not. Jackson et al.31 reported that low birth weight, lack of exclusive breast-feeding, crowding – more than seven persons per household, exposure to indoor air pollution, incomplete immunisation, undernutrition – weight-for-age less than two standard deviations and HIV infection were risk factors for severe pneumonia in children aged five years and below. A direct relationship could not be shown between the presence of atopy and severe pneumonia in our study, however the presence of ever wheezing, allergic disease story and parental asthma were associated with worse pneumonia.

Camara et al.35 carried out a study on children aged under 12 and reported that atopy history in the family for children under the age of two and the inhalant allergen sensitivity for children above the age of two were risk factors for viral respiratory tract infections. These findings are in accordance with our study. Kusel et al.36 evaluated children aged six months, two, five and ten years old who had severe viral respiratory tract infections with regard to atopy. While the rate of atopy was not increased at two years of age, it increased by 2.56 between the ages of 2–5 and by 17.14 times at the age of ten. This relationship was observed in cases who had severe RSV infection at an early age.

The average age of children with atopy was greater in comparison with the ages of those without atopy in our study (p = 0.001). Perhaps, different results may be obtained when in vitro methods such as sIgE are used instead of SPT to detect the presence of atopy at early ages. One of the limitations of our study was that atopic status has not been monitored at periodic intervals.

Hyvärinen et al.37 examined the effects of severe bronchiolitis and pneumonia during the infantile period on teenage asthma reporting that repeated wheezing, atopic dermatitis and elevated blood eosinophils were early asthma-predictive factors. It was also observed in our study that repeated wheezing and accompanying story of allergic disease were related with severe pneumonia.

The relation between persistent respiratory problems and socioeconomic status has been remarked in many studies.38,39 However, as the families in general did not want to say their actual level of income, we could not evaluate the economic status directly. We tried to indirectly evaluate according to their educational level. We can say that the socioeconomic level of the patients’ parents is generally middle class. The education status of the parents was not associated with both the severity of pneumonia and atopy.

By determining the risk factors for severe pneumonia, it will be possible to use various treatment modalities on these children at early ages and thus prevent the development of severe pneumonia. Persistent wheezing and asthma development at later ages will thus be prevented by preventing severe pneumonia at an early age. In our study, even though the presence of atopy was not a risk factor for severe pneumonia, history of atopy in patients who had severe lower respiratory tract infections may indicate that the disease may follow a severe course in atopic patients. Decreasing exposure to allergens in addition to decreasing ETS may also decrease the risk of severe lower respiratory tract infection.

Ethical disclosures

Confidentiality of data. The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study.

Right to privacy and informed consent. The authors have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence is in possession of this document.
Protection of human subjects and animals in research. The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.

Funding source
No external funding was secured for this study.

Contributors’ statement page
Semiha Bahçeci Erdem: literature search, study design, data collection, data analysis, manuscript preparation/editing, final manuscript approval.
Demet Can: literature search, study design, data collection, data analysis, manuscript preparation/editing, final manuscript approval.
Saniye Girit: literature search, study design, data collection, manuscript preparation/editing, final manuscript approval.
Ferhat Catal: literature search, data collection, manuscript preparation/editing.
Velat Sen: literature search, manuscript preparation/editing, data collection
Sevgi Pekcan: literature search, data collection, manuscript preparation/editing.
Hasan Yüksel: literature search, data collection, manuscript preparation/editing.
Ayşen Bingöl: literature search, manuscript preparation/editing, data collection.
Ilknur Bostancı: literature search, manuscript preparation/editing, data collection.
Duygu Erge: literature search, manuscript preparation/editing, data collection.
Refika Ersu: literature search, study design, data collection, manuscript preparation/editing, final manuscript approval.

Financial disclosure
The authors have no financial relationships relevant to this article to disclose.

Conflict of interest
The authors have no conflicts of interest to disclose.

References
1. Rowe RK, Gill MA. Asthma: the interplay between viral infections and allergic diseases. Immunol Allergy Clin North Am. 2015;35:115–27.
2. Boulet L, Bélanger M, Carrier G. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med. 1995;152:865–71.
3. Collins SA, Lockett GA, Holloway JW. The genetics of allergic disease and asthma. In: Leung DYM, Szefler SJ, Akdis CA, Bonilla FA, Sampson HA, editors. Pediatric allergy: principles and practice. 3rd ed. Toronto; 2016. p. 18–30.
4. Okayama Y. Cellular and humoral immunity of virus-induced asthma. Front Microbiol. 2013;4:252.
5. Gavala ML, Bashir H, Gern JE. Virus/allergen interactions in asthma. Curr Allergy Asthma Rep. 2013;13:298–307.
6. Kim YJ, Ryu SL, Jung SH, Shin JW, Kim DS, Jung HL, et al. Increased prevalence of H1N1-induced severe lower respiratory tract diseases in children with atopic sensitization. Allergy Asthma Immunol Res. 2012;4:277–83.
7. Dawood FS, Kamimoto L, D’Mello TA, Reingold A, Gershman K, Meek J, et al. Emerging Infections Program Network Children with asthma hospitalized with seasonal or pandemic influenza, 2003–2009. Pediatrics. 2011;128:27–32.
8. Hasegawa S, Hirano R, Hashimoto K, Haneda Y, Shirabe K, Ichiyama T. Characteristics of atopic children with pandemic H1N1 influenza viral infection: pandemic H1N1 influenza reveals ‘occult’ asthma of childhood. Pediatr Allergy Immunol. 2011;22:119–23.
9. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359:831–4.
10. Stensballe LG, Kristensen K, Simoes EA, Jensen H, Nielsen J, Benn CS, et al. Danish RSV Data Network. Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study. Pediatrics. 2006;118:1360–8.
11. Jung JA, Kita H, Yawn BP, Boyce TG, Yoo KH, McGree ME, et al. Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma. J Allergy Clin Immunol. 2010;125:217–21.
12. Kloepfer KM, Gern JE. Virus/allergen interactions and exacerbations of asthma. Immunol Allergy Clin North Am. 2010;30:553–63.
13. Ahanchian H, Jones CM, Chen YS, Sly PD. Respiratory viral infections in children with asthma: do they matter and can we prevent them? BMC Pediatrics. 2012;12:147.
14. Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68:1520–31.
15. Swindle EJ, Collins JE, Davies DE. Breakdown in epithelial barrier function in patients with asthma: identification of novel therapeutic approaches. J Allergy Clin Immunol. 2009;124:23–34.
16. Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur J Immunol. 2013;43:3125–37.
17. Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010;2:002907.
18. Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol. 2010;20:142–9.
19. Proud D, Leigh R. Epithelial cells and airway diseases. Immunol Rev. 2011;242:186–204.
20. Holgate ST. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev. 2011;242:205–19.
21. Sly PD, Boner AL, Björksten B, Bush A, Custovic A, Eigenmann PA, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet. 2008;372:1100–6.
22. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med. 1990;323:502–7.
23. Jacquett A. Interactions of airway epithelium with protease allergens in the allergic response. Clin Exp Allergy. 2011;41:305–11.
24. Van der Schans CP. Bronchial mucus transport. Respir Care. 2007;52:1150–6.
25. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucus in airwaysmucus. Annu Rev Physiol. 2008;70:459–86.
Grünberg K, Timmers MC, de Klerk EP, Dick EC, Sterk PJ. Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am J Respir Crit Care Med. 1999;160:1375-80.

Ducharme FM, Zemek R, Chauhan BF, Gravel J, Chalut D, Poonai N, et al. Factors associated with failure of emergency department management in children with acute moderate or severe asthma: a prospective, multicentre, cohort study. Lancet Respir Med. 2016;4:990-8.

Costa LD, Costa PS, Camargos PA. Exacerbation of asthma and airway infection: is the virus the villain? J Pediatr (Rio J). 2014;90:542-55.

Ahn A, Edwards KM, Grijalva CG, Self WH, Zhu Y, Chappell JD, et al. Secondhand smoke exposure and illness severity among children hospitalized with pneumonia. J Pediatr. 2015;167:869-74.

O’Dempsey TJ, McArdle TF, Morris J, Lloyd-Evans N, Baldeh I, Laurence BE, et al. A study of risk factors for pneumococcal disease among children in a rural area of West Africa. Int J Epidemiol. 1996;25:885-93.

Gessner BD, Ussery XT, Parkinson AJ, Breiman RF. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatr Infect Dis J. 1995;14:123-8.

Takala AK, Jero J, Kela E, Rönberg PR, Koskeniemi E, Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA. 1995;273:859-64.

Jroudi I, Mahraoui C, Bennessaoud R, Moraleda C, Tilgui H, Seffar M, et al. Risk factors for a poor outcome among children admitted with clinically severe pneumonia to a university hospital in Rabat, Morocco. Int J Infect Dis. 2014;28:164-70.

Lazzarini M, Seward N, Lufesi N, Banda R, Sinyeka S, Masache G, et al. Mortality and its risk factors in Malawian children admitted to hospital with clinical pneumonia, 2001-12: a retrospective observational study. Lancet Glob Health. 2016;4:57-68.

Jackson S, Mathews KH, Pulanic D, Falconer R, Rudan I, Campbell H, et al. Risk factors for severe acute lower respiratory infections in children: a systematic review and meta-analysis. Croat Med J. 2013;54:110-21.

Camara AA, Silva JM, Ferriani VP, Tobias KR, Macedo IS, Padovani MA, et al. Risk factors for wheezing in a subtropical environment: role of respiratory viruses and allergen sensitization. J Allergy Clin Immunol. 2004;113:551-7.

Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur Respir J. 2012;39:876-82.

Hyvärinen M, Piippo-Savolainen E, Korhonen K, Korppi M. Teenage asthma after severe infantile bronchiolitis or pneumonia. Acta Paediatr. 2005;94:1378-83.

Teijeiro A, Badellino H, Raiden MG, Cuello J, Kevorkof G, Gatti C, et al. Risk factors for recurrent wheezing in the first year of life in the city of Córdoba, Argentina. Allergol Immunopathol. 2016;44:30120-3.

Bhat RY, Manjunath N. Correlates of acute lower respiratory tract infections in children under 5 years of age in India. Int J Tuberc Lung Dis. 2013;17:418-22.